Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

April 2, 2019 0

Sangamo’s Stock Price Soars Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following …

Novartis’ Revolution: A new dimension and Prohost expectations

April 1, 2019 0

The Market is Outperforming Today. There is important news today about Novartis; part of which we …

Seattle Genetics: Why a selloff following good news

March 29, 2019 0

Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals’ product Sunosi

March 27, 2019 0

The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

March 26, 2019 0

While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

March 22, 2019 0

Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …

Biogen discontinued its Alzheimer’s disease drug Aducanumab. The usual selloff followed

March 21, 2019 0

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …

The FDA approves the first ever postpartum depression product. Positive results from Dermira’s atopic dermatitis product Lebrikizumab

March 20, 2019 0

News We Loved to Hear The First and Only Approval of a Specific Product for Postpartum …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

Atossa Genetics’ news that staged a huge Rally of this small firm’s stock

March 14, 2019 0

Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

March 12, 2019 0

We love to read news about gene therapy as it is the only possibility for curing …

Exelixis moves more products into clinical trials. Alnylam’s product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

March 6, 2019 0

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …

Good news and setbacks during the departed week

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Prohost Letter #430

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

Novartis’ Revolution: A new dimension and Prohost expectations

Seattle Genetics: Why a selloff following good news

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals’ product Sunosi

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

Biogen discontinued its Alzheimer’s disease drug Aducanumab. The usual selloff followed

The FDA approves the first ever postpartum depression product. Positive results from Dermira’s atopic dermatitis product Lebrikizumab

During the Departed Week

End of the Year Decisions ~ Part 4

Atossa Genetics’ news that staged a huge Rally of this small firm’s stock

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

Exelixis moves more products into clinical trials. Alnylam’s product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

Good news and setbacks during the departed week

Why CRISPR Therapeutics’ stock gained around $8 today

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

Cytokinetics’ heart failure drug omecamtiv mecarbil advancing into late phase trials

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

The Week in Review #37